Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 3/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23069318 | 1.00 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL2288403 | 1.00 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL24922846 | 1.00 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23244011 | 0.99 | LMNA (0.67) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL27417486 | 0.93 | LMNA (0.66) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23243977 | 0.92 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL19448748 | 0.92 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL19151249 | 0.92 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23243955 | 0.92 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT | |
| SCHEMBL23069319 | 0.92 | LMNA (0.68) | LMNAKMT2APOLBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | ARROWHEAD MADISON INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3023495-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | Arrowhead Research Corporation (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9345775-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Pharmaceuticals, Inc. | 2015-07-23 | — | — | US | disclosed |
| US-9011919-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2652134-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | Arrowhead Madison Inc. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2539451-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | Arrowhead Research Corporation (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8313772-B2 | Compositions for targeted delivery of siRNA | Arrowhead Madison Inc. (US) | 2012-11-20 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2011104169-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | ROCHE MADISON INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222384-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
| US-20150202298-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | GALK1, GALE, GALNT6 | LMNA 3401/4885KMT2A 1963/4885POLB 1068/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | LMNA 3401/4885KMT2A 1963/4885POLB 1068/4885 |
| US-20110207799-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
| US-20130245091-A1 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | LMNA 694/4885KMT2A 4037/4885POLB 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.